ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 70 filers reported holding ATEA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 3.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,177,782 | -15.8% | 1,725,729 | +4.9% | 0.00% | 0.0% |
| Q2 2023 | $6,152,442 | +23.3% | 1,645,038 | +10.4% | 0.00% | 0.0% |
| Q1 2023 | $4,991,714 | +72107.6% | 1,490,064 | +3.7% | 0.00% | 0.0% |
| Q4 2022 | $6,913 | -99.9% | 1,437,359 | +3.5% | 0.00% | 0.0% |
| Q3 2022 | $7,904,000 | -4.1% | 1,389,203 | +19.6% | 0.00% | 0.0% |
| Q2 2022 | $8,246,000 | +11.0% | 1,161,424 | +12.9% | 0.00% | 0.0% |
| Q1 2022 | $7,427,000 | -23.1% | 1,028,760 | -4.8% | 0.00% | 0.0% |
| Q4 2021 | $9,662,000 | -73.3% | 1,080,793 | +4.7% | 0.00% | -80.0% |
| Q3 2021 | $36,202,000 | +148.9% | 1,032,596 | +52.5% | 0.01% | +150.0% |
| Q2 2021 | $14,543,000 | -14.3% | 677,053 | +146.3% | 0.00% | -33.3% |
| Q1 2021 | $16,974,000 | +51.7% | 274,885 | +2.6% | 0.00% | +50.0% |
| Q4 2020 | $11,191,000 | – | 267,866 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |